Acoltremon clinical trials
Also written TRYPTYR®.
How each study uses acoltremon is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the acoltremon studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 May 2025 · TRYPTYR · NDA 217370 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 10
Aerie Pharmaceuticals (4) · Southern College of Optometry (4) · Alcon Research (3) · University of California, Berkeley (1) · Eye Research Associates, LLC (1) · University of South Florida (1) · Center for Sight Las Vegas (1) · NYU Langone Health (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test acoltremon.
- Nov 2026Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT)Phase 4 · Center for Sight Las Vegas
- Dec 2026Evaluating a New Therapy for Dry Eye in Patients With Sjögren's SyndromePhase 4 · Center For Sight
- Feb 2027Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%Phase 4 · Eye Research Associates, LLC
- Apr 2027TRYPTYR as a Treatment for Patients With Dry Eye Disease (DED)Phase 4 · NYU Langone Health
- May 2027Cooling Eyedrops for Dry EyePhase 4 · University of California, Berkeley
- May 2027Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal PainPhase 4 · University of South Florida
- Jul 2027Evaporative Dry EyePhase 4 · Southern College of Optometry
Studies
Open first, then newest update. How each study uses acoltremon is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Evaporative Dry EyeNot yet recruitingPhase 4Southern College of OptometryNCT07901647Written as acoltremon 0.003%.How we know
- Cooling Eyedrops for Dry EyeNot yet recruitingPhase 4University of California, BerkeleyNCT07888452Written as TRYPTYR Eye DropsHow we know
- Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%Not yet recruitingPhase 4Eye Research Associates, LLCNCT07848373Written as acoltremon 0.003%How we know
- Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal PainNot yet recruitingPhase 4University of South FloridaNCT07849803Written as acoltremon ophthalmic solution 0.003%How we know
- TRYPTYR as a Treatment for Patients With Dry Eye Disease (DED)RecruitingPhase 4NYU Langone HealthNCT07732010Written as TRYPTYR (Acoltremon ophthalmic solution 0.003%)How we know
- Evaluating a New Therapy for Dry Eye in Patients With Sjögren's SyndromeRecruitingPhase 4Center For SightNCT07277257Written as TRYPTYR (Acoltremon ophthalmic solution 0.003%)How we know
- Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT)Not yet recruitingPhase 4Center for Sight Las VegasNCT07281950Written as acoltremon 0.003%How we know
- Switching From Xiidra to TRYPTYRNot yet recruitingPhase 4Southern College of OptometryNCT07267481Written as acoltremon 0.003%How we know
- Switching From Restasis to TRYPTYRNot yet recruitingPhase 4Southern College of OptometryNCT07267299Written as acoltremon 0.003%How we know
- Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform WorkRecruitingPhase 4Southern College of OptometryNCT07266948Written as AcoltremonHow we know
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye DiseaseCompletedPhase 3Alcon ResearchNCT06544694Written as 0.003% AR-15512 ophthalmic solutionHow we know
- A Study to Evaluate 0.003% AR-15512 Safety and Drop AttributesCompletedPhase 3Alcon ResearchNCT06660290Written as 0.003% AR-15512 ophthalmic solutionHow we know
- A Study Designed to Evaluate Tear ProductionCompletedPhase 3Alcon ResearchNCT06544707Written as 0.003% AR-15512 ophthalmic solutionHow we know
- A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512CompletedPhase 3Aerie PharmaceuticalsNCT05493111Written as 0.003% AR-15512 ophthalmic solutionHow we know
- Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)CompletedPhase 3Aerie PharmaceuticalsNCT05360966Written as 0.003% AR-15512 ophthalmic solutionHow we know
- Study Evaluating the Safety and Efficacy of AR-15512CompletedPhase 3Aerie PharmaceuticalsNCT05285644Written as 0.003% AR-15512 ophthalmic solutionHow we know
- A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye DiseaseCompletedPhase 2Aerie PharmaceuticalsNCT04498182Written as AR-15512 Ophthalmic SolutionHow we know
- Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye SyndromeStatus unknownPhase 1/2Avizorex Pharma, S.L.NCT03162094Written as AVX012 Ophthalmic Solution Low doseHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered2
- Evaporative Dry EyeOct 28, 2026NCT07901647
- Cooling Eyedrops for Dry EyeOct 22, 2026NCT07888452
Codes
What other systems call acoltremon · ClinicalTrials.gg INT002150
- MeSH (NLM) C000731855acoltremonOne source NLM
- UNII (FDA) 1L7BVT4Z4ZACOLTREMONConfirmed FDA, NLM, Wikidata
- Wikidata Q27089230acoltremonConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C189962AcoltremonOne source FDA
- DrugBank DB19202One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731855 | acoltremon | One source NLM |
| UNII (FDA) | 1L7BVT4Z4Z | ACOLTREMON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27089230 | acoltremon | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C189962 | Acoltremon | One source FDA |
| DrugBank | DB19202 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.